| Cell adhesion molecules (CAMs) |
10 |
1.08E-02 |
OCLN, NLGN4X, CLDN1 |
HLA-DQB1, NTNG1, CNTN1, ITGB2, ITGA4, CLDN20, HLA-F |
2.72 |
| Glycosaminoglycan biosynthesis - heparan sulfate / heparin |
4 |
2.29E-02 |
XYLT1 |
HS3ST3A1, HS3ST2, HS3ST3B1 |
6.43 |
| ECM-receptor interaction |
7 |
2.43E-02 |
COL5A1 |
LAMA1, COL4A2, COL1A2, COL6A1, ITGA4, FN1 |
3.11 |
| Pathways in cancer |
18 |
2.43E-02 |
FZD10, FGFR3, MMP9, FGF2 |
LAMA1, FOS, PTGER1, COL4A2, RAC2, RAC3, RASGRP2, EGLN3, FGF13, HHIP, FZD2, GLI2, MMP1, FN1 |
1.77 |
| Regulation of actin cytoskeleton |
11 |
4.55E-02 |
FGFR3, SCIN, FGF2 |
CHRM4, RAC2, RAC3, FGF13, ITGB2, ITGA4, MYLK, FN1 |
2.01 |
| Focal adhesion |
10 |
8.41E-02 |
COL5A1 |
LAMA1, COL4A2, RAC2, RAC3, COL1A2, COL6A1, ITGA4, MYLK, FN1 |
1.87 |
| MAPK signaling pathway |
10 |
2.11E-01 |
FGFR3, FGF2, CACNA1A |
MEF2C, FOS, RAC2, RAC3, RASGRP2, DUSP10, FGF13 |
1.51 |
| cGMP-PKG signaling pathway |
7 |
2.56E-01 |
RGS2 |
MEF2C, KCNMB4, ATP1A4, ATP1A1, ADRA2C, MYLK |
1.63 |
| Transcriptional misregulation in cancer |
7 |
2.65E-01 |
LMO2, UTY, MMP9 |
MEF2C, FLI1, NGFR, MMP3 |
1.61 |
| PI3K-Akt signaling pathway |
12 |
2.75E-01 |
FGFR3, FGF2, COL5A1 |
LAMA1, COL4A2, COL1A2, COL6A1, FGF13, TLR4, NGFR, ITGA4, FN1 |
1.34 |
| Oxytocin signaling pathway |
6 |
3.85E-01 |
RGS2 |
MEF2C, FOS, KCNJ12, KCNJ2, MYLK |
1.47 |
| cAMP signaling pathway |
7 |
4.01E-01 |
|
FOS, RAC2, RAC3, ATP1A4, ATP1A1, HHIP, HTR1F |
1.36 |
| Adherens junction |
3 |
5.50E-01 |
|
PTPRB, RAC2, RAC3 |
1.63 |
| Tight junction |
4 |
6.91E-01 |
EPB41L3, OCLN, CLDN1 |
CLDN20 |
1.13 |
